Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Br J Haematol. 2015 Jan 22;169(3):344–351. doi: 10.1111/bjh.13299

Figure 5.

Figure 5

Survival analysis of AML cases categorized by RUNX3 methylation status. (A) Non-inv(16) AMLs have poor overall survival that does not differ between RUNX3 hypermethylated (solid line) and unmethylated groups (dotted line). (B) Relapse-free survival was significantly longer in unmethylated RUNX3 non-inv(16) cases. (C and D) Trend toward longer overall and relapse-free survival in unmethylated RUNX3 inv(16) AML cases but not statistically significant.